Pancreatogenic diabetes: Special considerations for management

Pancreatology

Volumn 11, Issue 3, 2011, Pages 279-294

  Cui, YunFeng ^a,b   Andersen, Dana K ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic insulin resistance; Metformin; Pancreatic cancer; Pancreatic exocrine insufficiency; Pancreatic polypeptide; Pancreatogenic diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; EXENDIN 4; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PANCREAS ENZYME; PANCREAS POLYPEPTIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SOMATOMEDIN; SULFONYLUREA;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BEDTIME DOSAGE; CANCER RISK; CHRONIC PANCREATITIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ENZYME THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC BONE DISEASE; MORNING DOSAGE; NUTRITIONAL DEFICIENCY; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREAS EXOCRINE INSUFFICIENCY; PANCREATOGENIC DIABETES; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 79960241808     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000329188     Document Type: Review

References (114)

1. American Diabetes Association: Diagnosis and classification of diabetes. Diab Care 2011;34(suppl 1):S62-S69.
2. Centers for Disease Control. National Diabetes Fact Sheet, 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Updated 2007. Accessed 1/26/10.
3. Tiengo A, Alberti KG, Del Prato S, et al: Diabetes secondary to pancreatopathy: new pancreatopathy; in Tiengo A, Alberti KG, Del Prato S, Vranic M (eds): Diabetes Secondary to Pancreatopathy. Proceedings of the Post EASD International Symposium on Diabetes Secondary to Pancreatopathy, Padova, 21-22 September 1987. International Congress Series 762. Amsterdam, Excerpta Medica, 1988, pp 35-50.
4. Alberti KG: Diabetes secondary to pancreatopathy: an example of brittle diabetes; in Tiengo A, Alberti KG, Del Prato S, Vranic M (eds): Diabetes Secondary to Pancreatopathy. Proceedings of the Post EASD International Symposium on Diabetes Secondary to Pancreatopathy, Padova, 21-22 September 1987, International Congress Series 762. Amsterdam, Excerpta Medica, 1988, pp 211-214.
5. Ganda O: Secondary forms of diabetes; in Kahn CR, Weir GC (eds): Joslin's Diabetes Mellitus. New York, Lea & Febiger, 1994.
6. Abu-Bakare A, Taylor R, Gill GV, et al: Tropical or malnutrition-related diabetes: a real syndrome? Lancet 1986;1:1135-1138. (Pubitemid 16109969)
7. Mohan V, Pitchumoni C: Tropical chronic pancreatitis; in Beger HG (ed): The Pancreas. London, Blackwell Science, 1998, pp 688-697.
8. Hardt PD, Kloer HU, Brendel MD, Bretzel RG: Is pancreatic (type 3c) diabetes underdiagnosed and misdiagnosed? Diab Care 2008;31(suppl 2):S165-S169.
9. Ewald N, Raspe A, Kaufmann C, et al: Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentrations in patients with diabetes mellitus. Eur J Med Res 2009;14:1-6.
10. Bank S: Chronic pancreatitis: clinical features and medical management. Am J Gastroenterol 1986;81:153-167. (Pubitemid 16013309)
11. Nyboe Andersen B, Krarup T, Thorsgaard Pedersen NT, et al: B-cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function. Diabetologia 1982;23:86-89. (Pubitemid 12093492)
12. Malka D, Hammel P, Sauvanet A, et al: Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology 2000;119:1324-1332.
13. Slezak LA, Andersen DK: Pancreatic resection: effects on glucose metabolism. World J Surg 2001;25:452-460. (Pubitemid 32455198)
14. Hutchins RR, Hart RS, Pacifico M, Bradley NJ, Williamson RC: Long-term results of distal pancreatectomy for chronic pancreatitis in 90 patients. Ann Surg 2002;236:612-618. (Pubitemid 35246893)
15. King J, Kazanjian K, Matsumoto J, Reber HA, Yeh MW, Hines OJ, Eibl G: Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg 2008;12:1548-1553.
16. Olsen TS: The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material. Acta Pathol Microbiol Scand A 1978;86:361-364.
17. Worning H: Alcoholic chronic pancreatitis; in Beger HG (ed): The Pancreas. London, Blackwell Science, 1998, pp 672-679.
18. Rothenbacher D, Low M, Hardt PD, et al: Prevalence and determinants of exocrine pancreatitic insufficiency among older adults: results of a population-based study. Scand J Gastroenterol 2005;40:697-704. (Pubitemid 40827532)
19. Cunningham JD, O'Donnell N, Starker P: Surgical outcomes following pancreatic resection at a low-volume community hospital: do all patients need to be sent to a regional cancer center? Am J Surg 2009;198:227-230.
20. Helm JF, Centeno BA, Coppola D, Druta M, Park JY, Chen DT, Hodul PJ, Kvols LK, Yeatman TJ, Carey LC, Karl RC, Malafa MP: Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control 2008;15:288-294.
21. Moran A, Becker D, Casella SJ, et al: Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes. A technical review. Diab Care 2010;33:2677-2683.
22. Bliss M: The Discovery of Insulin. Chicago, University of Chicago Press, 1984.
23. Nosadini R, del Prato S, Tiengo A, et al: Insulin sensitivity, binding, and kinetics in pancreatogenic and type 1 diabetes. Diabetes 1982;31:346-355. (Pubitemid 12135299)
24. Andres R, Swerdloff R, Pozefsky T, et al: Manual feedback technique for control of glucose concentration; in Skeggs L Jr (ed): Automation in Analytic Chemistry. New York, Medaid Inc, 1966, pp 486-501.
25. Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959;82:420-430.
26. Sun YS, Brunicardi FC, Druck P, et al: Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide. Am J Surg 1986;151:130-140. (Pubitemid 16143194)
27. Yeo CJ, Bastidas JA, Schmieg RE Jr, et al: Pancreatic structure and glucose tolerance in a longitudinal study of experimental pancreatitisinduced diabetes. Ann Surg 1989;210:150-158. (Pubitemid 19188704)
28. Cerosimo E, Pisters PW, Pescola G, et al: Insulin secretion and action in patients with pancreatic cancer. Cancer 1991;67:486-493.
29. Andersen DK: Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. Pancreas 2007;35:1-15. (Pubitemid 46956195)
30. Kien CL, Horswill CA, Zipf SB, et al: Elevated hepatic glucose production in children with cystic fibrosis. Pediatr Res 1995;37:600-605.
31. Sive A, Vinik AI, Van Tonder S, Lund A: Impaired pancreatic polypeptide secretion in chronic pancreatitis. J Clin Endocrinol Metab 1978;47:556-559. (Pubitemid 9010406)
32. Inoue K, Tobe T, Suzuki T, et al: Plasma cholecystokinin and pancreatic polypeptide after radical pancreaticoduodenectomy with Billroth I and Billroth II types of reconstruction. Ann Surg 1986;206:148-154. (Pubitemid 17104957)
33. Adiran TE, McKiernan J, Johnstone DI, et al: Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology 1980;79:460-465. (Pubitemid 10056391)
34. Bastidas JA, Couse NF, Yeo CJ, et al: The effect of pancreatic polypeptide infusion on glucose tolerance and insulin response in longitudinally studied pancreatitis-induced diabetes. Surgery 1990;107:661-668. (Pubitemid 20182656)
35. Seymour NE, Brunicardi FC, Chaiken RL, Lebovitz HE, Chance RE, Gingerich RL, Elahi D, Andersen DK: Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery 1988;104:119-129.
36. Brunicardi FC, Chaiken RL, Ryan AS, et al: Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 1996;81:3566-3572. (Pubitemid 26339916)
37. Mundlos S, Adler G, Schaar M, et al: Exocrine pancreatic function in oleic acid-induced pancreatic insufficiency in rats. Pancreas 1986;1:29-36.
38. Seymour NE, Turk JB, Laster MK, et al: In vitro hepatic insulin resistance in chronic pancreatitis in the rat. J Surg Res 1989;46:450-456. (Pubitemid 19148972)
39. Seymour NE, Andersen DK: Pancreatic polypeptide and glucose metabolism; in Greeley GH (ed): Gastrointestinal Endocrinology. Totowa, Humana Press, 1999, pp 321-334.
40. Goldstein JA, Kirwin JD, Seymour NE, et al: Reversal of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide in the rat. Surgery 1989;106:1128-1132.
41. Seymour NE, Volpert AR, Lee EL, et al: Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg 1995;169:105-110.
42. Seymour NE, Spector SA, Andersen DK, et al: Overexpression of hepatic pancreatic polypeptide receptors in chronic pancreatitis. J Surg Res 1998;76:47-52. (Pubitemid 28363853)
43. Spector SA, Frattini JC, Zdankiewicz PD, et al: Insulin receptor gene expression in chronic pancreatitis: the effect of pancreatic polypeptide. Surg Forum 1997;48:168-171.
44. Andersen DK, Ruiz CL, Burant CF: Insulin regulation of hepatic glucose transporter protein is impaired in chronic pancreatitis. Ann Surg 1994;219:679-686.
45. Nathan JD, Zdankiewicz PD, Wang JP, et al: Impaired hepatocyte glucose transport protein (GLUT2) internalization in chronic pancreatitis. Pancreas 2001;22:172-178. (Pubitemid 32179172)
46. Eisenberg ML, Maker AV, Slezak LA, et al: Insulin receptor and glucose transporter 2 proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem 2005;15:51-58.
47. Seymour NE, Andersen DK: Pancreatic Polypeptide and glucose metabolism; in Greeley GH (ed): Gastrointestinal Endocrinology. Totowa, Humana Press, 1999, pp 321-334.
48. Kono T, Wang XP, Fisher WE, et al: Pancreatic polypeptide; in Martini L (ed): Encyclopedia of Endocrine Diseases. San Diego, Elsevier, 2004, vol 3, pp 488-496.
49. Donowitz M, Hendler R, Spiro HM, et al: Glucagon secretion in acute and chronic pancreatitis. Ann Intern Med 1975;83:778-781.
50. Ebert R, Creutzfeldt WO: Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 1980;19:198-204. (Pubitemid 10003179)
51. Knop FK, Visboll T, Larsen S, et al: Increased post-prandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 2007;292:E324-E330. (Pubitemid 46052957)
52. Frey CF, Child CG, Fry W: Pancreatectomy for chronic pancreatitis. Ann Surg 1976;184:403-413.
53. Gall FP, Muhe E, Gebhardt C: Results of partial and total pancreatectomy in 117 patients with chronic pancreatitis. World J Surg 1981;5:269-275. (Pubitemid 11088127)
54. Couet C, Genton P, Pointel JP, et al: The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus. Diab Care 1985;8:323-328. (Pubitemid 15043151)
55. Aspelund G, Topazian MD, Lee JH, et al: Improved outcomes for benign disease with limited pancreatic head resection. J Gastrointest Surg 2005;9:400-409. (Pubitemid 40327111)
56. Berstein LM: Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 2005;224:203-212. (Pubitemid 40731528)
57. Riddle MC, Drucker DJ: Emerging therapies mimicking the effects of amylin and glucagonlike peptide 1. Diab Care 2006;29:435-449. (Pubitemid 44106536)
58. Masharani U, German MS: Pancreatic hormones and diabetes mellitus; in Gardner DG, Shoback D (eds): Greenspan's Basic and Clinical Endocrinology (8e: http://www.accessmedicine.com/content.aspx?aID=2633151).
59. Lebovitz HE: Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:326-334.
60. Jemal A, Siegel R, Ward E, et al: Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
61. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
62. Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-1437. (Pubitemid 23143844)
63. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R: Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010;24:349-358.
64. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al: Type 2 diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-2083. (Pubitemid 40897433)
65. Wideroff L, Gridley G, Mellemkjaer L, et al: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-1365. (Pubitemid 27418027)
66. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625-1638. (Pubitemid 36459468)
67. Magruder JT, Elahi D, Andersen DK: Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011;40:339-351.
68. Inoue M, Iwasaki M, Otani T, et al: Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-1877. (Pubitemid 44455170)
69. Saydah SH, Platz EA, Rifai N, et al: Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarker Prevent 2003;12:412-418. (Pubitemid 36578478)
70. Batty GD, Shipley MJ, Marmot M, et al: Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 2004;15:873-881. (Pubitemid 39663863)
71. Jee SH, Ohrr H, Sull JW, et al: Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202. (Pubitemid 40095870)
72. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al: Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-2878. (Pubitemid 41785868)
73. Butler AE, Galasso R, Matveyenko A, et al: Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010;53:21-26.
74. Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008;8:915-928.
75. Rozengurt E, Sinnett-Smith J, Kisfalvi K: Crosstalk between insulin/insulin-like growth factor-1 receptors and G-proteincoupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010;16:2505-2511.
76. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23-37. (Pubitemid 351998752)
77. Belfiore A: The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-686. (Pubitemid 46510744)
78. Azar M, Lyons TJ: Diabetes, insulin treatment, and cancer risk: what is the evidence? F1000 Med Rep 2010;2(pii):4.
79. Ding XZ, Fehsenfeld DM, Murphy LO, et al: Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 2000;21:310-320.
80. Bonelli L, Aste H, Bovo P, et al: Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003;27:143-149. (Pubitemid 36950726)
81. Bowker SL, Majumdar SR, Veugelers P, et al: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diab Care 2006;29:254-258. (Pubitemid 44106500)
82. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al: Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann Epidemiol 2010;20:92-98.
83. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305. (Pubitemid 40813563)
84. Libby G, Donnelly LA, Donnan PT, et al: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diab Care 2009;32:1620-1625.
85. Li D, Yeung SC, Hassan MM, et al: Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-488.
86. Schneider MB, Matsuzaki H, Haorah J, et al: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-1270. (Pubitemid 32246678)
87. Shaw RJ, Lamia KA, Vasquez D, et al: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-1646. (Pubitemid 41780780)
88. Zakikhani M, Dowling R, Fantus IG, et al: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273. (Pubitemid 44799743)
89. Kisfalvi K, Eibl G, Sinnett-Smith J, et al: Metformin disrupts crosstalk between G-proteincoupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009;69:6539-6545.
90. Shaw RJ, Bardeesy N, Manning BD, et al: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-99. (Pubitemid 38903165)
91. Alessi DR, Sakamoto K, Bayascas JR: LKB1-dependent signaling pathways. Annu Rev Biochem 2006;75:137-163. (Pubitemid 44118029)
92. Rozengurt E: Mitogenic signaling pathways induced by G-protein-coupled receptors. J Cell Physiol 2007;213:589-602. (Pubitemid 350058250)
93. Dowling RJ, Zakikhani M, Fantus IG, et al: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-10812. (Pubitemid 350145909)
94. Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110:246-250.
95. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-3302.
96. Maida A, Lamont BJ, Cao X, Drucker DJ: Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011;54:339-349.
97. Stoffers DA, Kieffer TJ, Hussain MA, et al: Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000;49:741-748. (Pubitemid 30339989)
98. Matveyenko AV, Dry S, Cox HI, et al: Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604-1615.
99. Moran A, Brunzell C, Cohen RC, et al: Clinical care guidelines for cystic fibrosisrelated diabetes. Diab Care 2010;33:2697-2708.
100. Kirk D, Buse JB: Clinical care guidelines: too much of a good thing? Diab Care 2010;33:2716-2717.
101. American Diabetes Association: Standards of medical care in diabetes - 2011. Diab Care 2011;34(suppl 1):S11-S61.
102. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA 2003;289:2254-2264. (Pubitemid 37430194)
103. Mooradian AD, Bernbaum M, Albert SG: Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006;145:125-134. (Pubitemid 46780586)
104. Nathan DM, Holman RR, Buse JB, et al: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diab Care 2009;32:193-203.
105. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes: The Diabetes Control and Complications Trial. N Engl J Med 1993;329:978-986.
106. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
107. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
108. Lund SS, Tarnow L, Astrup AS, et al: Effect of adjuvant metformin treatment in patients with type 1 diabetes and persistent inadequate glycemic control. A randomized study. PLoS ONE 2008;3(10):e3363.
109. Riccardi G, Giacco R, Parillo M, et al: Efficacy and safety of acerbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999;16:228-232.
110. Rabiee A, Galiatsatos P, Salas-Carrillo R, et al: Pancreatic polypeptide infusion increases insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. J Diab Sci Technol 2011 (in press).
111. Hardt PD, Hauenschild A, Nalop J, et al: High prevalence of exocrine pancreatic insufficiency in diabetes mellitus: a multicenter study screening fecal elastase-1 concentrations in 1, 021 diabetic patients. Pancreatology 2003;3:395-403.
112. Mann, ST, Stracke H, Lange U, et al: Alterations in bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis. Metabolism 2003;52:579-585. (Pubitemid 36896284)
113. Loser C, Mollgaard A, Folsch UR: Faecal elastase-1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996;39:580-586. (Pubitemid 26376043)
114. Domínguez-Muñoz JE, Iglesias-García J, Vilariño-Insua M, et al: 13 C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2007;5:484-488. (Pubitemid 46575367)